Date: 2014-01-07
Type of information: Fundraising
Company: Isarna Therapeutics (Germany)
Investors: AT NewTec (Germany), MIG-managed funds (Germany)
Amount: € 13 Million
Funding type: fundraising
Planned used: Proceeds will be used to advance the company\'s pipeline of next generation oligonucleotides that inhibit various isoforms of TGF-β, a key molecular pathway implicated in mechanisms used by cancer cells to evade immune system detection and to aid in tumor proliferation.
Others:
Therapeutic area: Cancer - Oncology